Jubilant Ingrevia Ltd. · NSE:JUBLINGREA
Jubilant Ingrevia — Q1 FY2022 Earnings Presentation
19 slides from Jubilant Ingrevia's earnings presentation, Jul 20, 2021
Slide 1: Financial Results Quarter Ended June 30, 2021
Financial Results Quarter Ended June 30, 2021
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : July 20, 2021 Time : 05:00 pm IST Conference Dial-In Numbers + 91 22 6280 1141 Universal Access: + 91 22 7115 8042 USA: 1 866 746 2133 Toll Free Number: UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 Available from July 20 to July 27, 2021 Replay Fac
Slide 4: Chairmen's Message
Chairmen’s Message Mr. Shyam S Bhartia Mr. Hari S Bhartia Chairman Co-Chairman “With immense pleasure I would like to announce that we have started the FY22 with a very positive note by delivering our record quarterly financial performance so far. Along with managing COVID-19 related challenges, we
Slide 5: Financial Highlights: Improvement in all Key Financial Parameters
Financial Highlights1 : Improvement in all Key Financial Parameters Highlights Q1’FY22 ₹ 1,145 Cr. ₹ 287 Cr. 25.1% ₹ 168 Cr. 14.7% ₹ 10.6 Sales EBITDA EBITDA (%) PAT PAT (%) EPS 55% YoY 126% YoY 786 bps 220% YoY 756 bps 220% YoY Highlights ₹ 737 Cr. ₹ 127 Cr. 17.3% ₹ 53 Cr. 7.1% ₹ 3.3 Q1’FY21 2 Sale
Slide 6: Jubilant Ingrevia: Business Segments & Integrated Operations
Jubilant Ingrevia: Business Segments & Integrated Operations Integrated Operations… Vertical integration across the value chain enables cost competitive advantage Nutrition & For Vitamin B3 (Niacinamide & Niacin), 100% in-house sourcing of Beta Picoline Speciality Nutrition & Health Life Science H
Slide 7: Q1'FY22 Results Analysis
Q1'FY22 Results Analysis INGREVIA
Slide 8: Jubilant Ingrevia – Q1'FY22 Financial Highlights
Jubilant Ingrevia – Q1'FY22 Financial Highlights Particulars1 Q1'FY212 Q1'FY22 YoY (%) • Revenue grew by 55% on YoY basis, driven by robust growth in volume and prices. Revenue • Speciality Chemicals revenue grew by 18% YoY driven by volume growth across Speciality Chemicals 257 305 18% product segm
Slide 9: Specialty Chemicals: Market and Business Highlights
Specialty Chemicals: Market and Business Highlights - Overall demand continues to be strong. Domestic demand continues to improve due to shift of some of the Pharmaceutical & Agrochemical end products customers from China to India Market - The fresh wave of COVID-19 in India during Q1’FY22 led the i
Slide 10: Speciality Chemicals Segment Highlights – Q1'FY22
Speciality Chemicals Segment Highlights – Q1'FY22 Specialty Chemicals revenue grew by 18% on YoY basis Particulars1 Q1'FY212 Q1'FY22 YoY (%) driven by higher volume across product segments Revenue 257 305 18% North America revenue grew significantly, percentage Reported EBITDA 69 84 22% share to
Slide 11: Nutrition & Health Solutions: Market and Business Highlights
Nutrition & Health Solutions: Market and Business highlights - During the quarter, there has been volatility in demand of Vitamin B3 (Niacinamide & Niacin) due to global pandemic situation, however the demand has started picking up towards the end of the quarter. Market - Pandemic created some suppl
Slide 12: Nutrition & Health Solutions Segment Highlights – Q1'FY22
Nutrition & Health Solutions Segment Highlights – Q1'FY22 Particulars1 Q1'FY212 Q1'FY22 YoY (%) Nutrition and Health Solutions revenue grew by 13% Revenue 148 167 13% on YoY basis. Reported EBITDA 31 27 (15%) • Growth was driven by prices and growth in Reported EBITDA Margin (%) 21.0% 15.9% Niacin
Slide 13: Life Science Chemicals: Market and Business Highlights
Life Science Chemicals: Market and Business Highlights - Life Sciences Chemical market condition remained favourable due to disruption created by URI storm in southern industrial states of US, which impacted availability of Acetic Acid and Acetic Anhydride. The availability of both the products star
Slide 14: Life Science Chemicals Segment Highlights – Q1'FY22
Life Science Chemicals Segment Highlights – Q1'FY22 Particulars1 Q1'FY212 Q1'FY22 YoY (%) Life Sciences Chemicals revenue grew by 103% on YoY basis Revenue 331 673 103% • Life Sciences Chemical revenue growth was driven by Reported EBITDA 24 184 677% higher volume as well as prices. Reported EBITD
Slide 15: Debt Profile – Q1 FY22
Debt Profile – Q1 FY22 Particulars1 31/Mar/21 30/Jun/21 Long Term Borrowings 456 227 Short Term Borrowings 92 230 Total 548 457 Cash & Equivalent 117 70 Net Debt 431 386 QoQ change - -10% Gross Debt reduction of Rs 91 Crore in Q1’FY 22. Net Debt reduction of Rs 45 Crore in Q1’FY22. Net Debt to
Slide 16: Business outlook
Business outlook Our businesses remain strong and during the year we expect to deliver better performance over last year. The Input prices continue to increase and the efforts to pass on the increases are being made continuously Our ongoing Diketene Capex is as per schedule, and it will be com
Slide 17: Income Statement – Q1 FY22
Income Statement – Q1 FY22 Particulars1 Q1'FY212 Q1'FY22 YoY (%) Total Revenue from Operations 737 1,145 55% Speciality Chemicals 257 305 18% Nutrition & Health Solutions 148 167 13% Life Science Chemicals 331 673 103% Total Expenditure 614 863 (41%) Other Income 4 6 Segment EBITDA Speciality Chemic
Slide 18: For More Information
For More Information For Investors: Hemant Bakhru | Pavleen Taneja Siddharth Rangnekar Ph: +91 120 436 1002| 21 CDR India E-mail: hemant.bakhru@jubl.com Ph: +91 22 6645 1209 pavleen.taneja@jubl.com E-mail: siddharth@cdr-india.com For Media: Sudhakar Safaya Clayton Dsouza Ph: +91 120 436 1034 Madison
Slide 19: Our Vision, Values, Promise and Philosophy
Our Vision, Values, Promise and Philosophy OUR PHILOSOPHY Caring Sharing Growing 19